MedTrace Logo

Effectiveness of Genistein in Mild Cognitive Impairment

NCT07385937 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-02-17

No results posted yet for this study

Summary

Randomized, placebo-controlled, double-blind, multicenter clinical trial with two parallel study arms (experimental and placebo) to assess the efficacy of genistein extract consumption over 18 months on cognitive decline in patients with prodromal Alzheimer's disease.

Conditions

  • Alzheimer Disease (AD)
  • Mild Cognitive Impairment (MCI)

Interventions

DIETARY_SUPPLEMENT

Genistein

Soy isoflavone

DIETARY_SUPPLEMENT

Control product placebo

It will be supplied in a color and shape similar to the active product, but with maltodextrin, an inert substance.

Sponsors & Collaborators

  • Universidad Católica San Antonio de Murcia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2027-07-31
Completion
2027-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07385937 on ClinicalTrials.gov